西妥昔单抗对人食管癌放射抗拒性细胞株KYSE-150R放射敏感性的研究  

Cetuximab enhances the radiosensitivity of radioresistant human esophageal squamous carcinoma cell line KYSE-150R

作　　者：李海英[1] 张力[2] 吴建波[1] 苏华芳[2] 吴式琇[2] 

机构地区：[1]温州医学院附属第一医院医科所,325000 [2]温州医学院附属第一医院放疗科,325000

出　　处：《中华放射医学与防护杂志》2010年第3期291-294,共4页Chinese Journal of Radiological Medicine and Protection

摘　　要：目的 观察西妥昔单抗（C225）对人食管鳞癌放射抗拒性细胞株KYSE-150R的影响.方法 分次照射建立人食管鳞癌放射抗拒性细胞株KYSE-150R;相差显微镜下观察细胞的形态学差异;G显带法进行染色体分析;克隆形成实验验证KYSE-150和KYSE-150R细胞的不同放射敏感性;采用不同浓度的C225处理KYSE-150R细胞,研究对KYSE-150R细胞放射敏感性的影响.结果 KYSE-150R细胞的群体倍增时间为（25.9±0.6）h,长于亲代细胞的KYSE-150（23.6±0.2）h（t=6.6,P〈0.01）;KYSE-150R细胞的染色体数目由69.3±1.9增加到73.7±1.2（t=8.83,P〈0.01）,并且观察到有染色体畸变;KYSE-150R细胞SF2、D0、Dq及N值均高于KYSE-150细胞,加入5μg/ml的C225后,其SF2、D0、Dq、N与单纯照射组KYSE-150R细胞相比有显著降低;加入C225后KYSE-150R细胞G0/G1、G2/M期比例增加,S期比例减少（t=-4.478～4.308,P〈0.05）.结论 C225对人食管鳞癌放射抗拒性细胞株KYSE-150R有放射增敏作用.Objective To determine the effect of cetuximab（C225）on the radioresistant human esophageal squamous carcinoma eell line KYSE-150R.Methods A radioresistant human esophageal squamous carcinoma cell line KYSE-150R was established by fractionated irradiation.Morphological changes from KYSE-150 to KYSE-150R were observed by phase-contrast microscopy.Karyotype analysis was performed by G-banding.The radiosensitivities were analyzed by colony formation assays.Results The population doubling time of KYSE-150 and KYSE-150R were（23.6±0.2）h and（25.9±0.6）h （t=6.6,P〈0.01）,respectively.The chromosome number of KYSE-150R was increased and chromosome aberrations were observed from（69.3±1.9）h to（73.7±1.2）h（t=-8.83,P〈0.01）.The SF2,D0,Dq and N values of KYSE-150R were all higher than those of KYSE-150.After 5μg/ml of C225 added,the SF2,D0,Dq and N values were significantly decreased as compared to the control.After C225 treatment,the G0/G1 and G2/M phase cells were increased,while S-phase cells decreased（t=-4.478-4.308,P〈0.05）.Conclusion Cetuximab can enhance the radiosensitivity of radioresistant human esophageal squamous carcinoma cell line KYSE-150R.

关 键 词：食管癌 放射敏感性 西妥昔单抗 

分 类 号：R735.1[医药卫生—肿瘤]